JHPCY (Jiangsu Hengrui Pharmaceuticals Co) Cyclically Adjusted PB Ratio: (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JHPCY Jiangsu Hengrui Pharmaceuticals Co Ltd JHPCY
71 GF Score
Price $13.60
GF Value $15.12
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jiangsu Hengrui Pharmaceuticals Co  (OTCPK:JHPCY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio Related Terms


Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.64 12.39 12.54 11.04 12.21

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.43 11.60 15.29 12.21 10.85

JHPCY vs ZTS, UTHR: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted PB Ratio falls into.


JHPCY
71GF Score
Jiangsu Hengrui Pharmaceuticals Co Ltd JHPCY
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Hengrui Pharmaceuticals Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Jiangsu Hengrui Pharmaceuticals Co's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Jiangsu Hengrui Pharmaceuticals Co's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.782/330.2130*330.2130
=2.782

Current CPI (Mar. 2026) = 330.2130.

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.531 241.018 0.728
201609 0.556 241.428 0.760
201612 0.566 241.432 0.774
201703 0.605 243.801 0.819
201706 0.634 244.955 0.855
201709 0.694 246.819 0.928
201712 0.737 246.524 0.987
201803 0.816 249.554 1.080
201806 0.830 251.989 1.088
201809 0.851 252.439 1.113
201812 0.907 251.233 1.192
201903 0.956 254.202 1.242
201906 0.991 256.143 1.278
201909 1.022 256.759 1.314
201912 1.109 256.974 1.425
202003 1.168 258.115 1.494
202006 1.177 257.797 1.508
202009 1.296 260.280 1.644
202012 1.458 260.474 1.848
202103 1.546 264.877 1.927
202106 1.595 271.696 1.939
202109 1.658 274.310 1.996
202112 1.718 278.802 2.035
202203 1.791 287.504 2.057
202206 1.689 296.311 1.882
202209 1.642 296.808 1.827
202212 1.701 296.797 1.893
202303 1.770 301.836 1.936
202306 1.701 305.109 1.841
202309 1.703 307.789 1.827
202312 1.777 306.746 1.913
202403 1.823 312.332 1.927
202406 1.842 314.175 1.936
202409 1.939 315.301 2.031
202412 1.960 315.605 2.051
202503 1.963 319.799 2.027
202506 2.454 322.561 2.512
202509 2.517 324.800 2.559
202512 2.621 324.054 2.671
202603 2.782 330.213 2.782

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Jiangsu Hengrui Pharmaceuticals Co (JHPCY) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued. The current stock price of $13.60 is trading 10.1% below its estimated GF Value™ of $15.12. GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.

Key valuation signals for JHPCY:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $15.12 vs. price of $13.60 (10.1% below fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the JHPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Address No. 7, Kunlunshan Road, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222000
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
71GF Score

Get the complete analysis for JHPCY

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.60
Price
$15.12
GF Value